Natalizumab-induced acquired perforating dermatosis

Clin Exp Dermatol. 2021 Oct;46(7):1373-1375. doi: 10.1111/ced.14699. Epub 2021 Jun 4.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Humans
  • Immunologic Factors / adverse effects*
  • Immunologic Factors / therapeutic use
  • Male
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • Natalizumab / adverse effects*
  • Natalizumab / therapeutic use
  • Pruritus / chemically induced*
  • Skin / pathology
  • Skin Diseases / chemically induced*
  • Skin Diseases / pathology

Substances

  • Immunologic Factors
  • Natalizumab